Skip to main content
PRME
NASDAQ Life Sciences

FDA Grants Prime Medicine's PM359 RMAT Status, Expediting Review for CGD

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$3.24
Mkt Cap
$583.394M
52W Low
$1.555
52W High
$6.94
52W Position info
108% above low
Off High info
53% below high
Rel. Volume info
1.4× avg
Market data snapshot near publication time

PRME has more than doubled off its 52-week low of $1.555.

Summary

Prime Medicine has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for PM359, its investigational therapy for Chronic Granulomatous Disease (CGD). This designation, based on positive Phase 1/2 clinical data, provides significant benefits including intensive FDA guidance, eligibility for rolling and priority review, and potential for accelerated approval. This substantially de-risks and accelerates the development pathway for a key pipeline asset, which is crucial for a company that recently reported Q1 2026 results with a 'going concern' warning. PM359 also holds Fast Track, Orphan Drug, and Rare Pediatric Disease Designations.

At the time of this announcement, PRME was trading at $3.24 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $583.4M. The 52-week trading range was $1.55 to $6.94. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

PRME - Latest Insights

PRME
Nov 10, 2026, 9:41 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $3.76
Real-time Price: $3.85 info
Change: +$0.0905 (+2%) info
Market Cap: $707.37M info
PRME
Nov 10, 2026, 4:43 PM EST
Filing Type: 424B5
Importance Score:
8
Price at Filing: $3.79
Real-time Price: $3.85 info
Change: +$0.060 (+2%) info
Market Cap: $707.37M info
PRME
Nov 10, 2026, 4:06 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.80
Real-time Price: $3.85 info
Change: +$0.050 (+1%) info
Market Cap: $707.37M info
PRME
Nov 10, 2026, 4:05 PM EST
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $3.81
Real-time Price: $3.85 info
Change: +$0.0399 (+1%) info
Market Cap: $707.37M info
PRME
Oct 28, 2026, 1:53 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $5.16
Real-time Price: $3.85 info
Change: -$1.31 (-25%) info
Market Cap: $707.37M info